AR039164A1 - Sales de venlafaxina de baja solubilidad en agua - Google Patents

Sales de venlafaxina de baja solubilidad en agua

Info

Publication number
AR039164A1
AR039164A1 ARP030101072A ARP030101072A AR039164A1 AR 039164 A1 AR039164 A1 AR 039164A1 AR P030101072 A ARP030101072 A AR P030101072A AR P030101072 A ARP030101072 A AR P030101072A AR 039164 A1 AR039164 A1 AR 039164A1
Authority
AR
Argentina
Prior art keywords
venlafaxine
water solubility
low water
compound
besylate
Prior art date
Application number
ARP030101072A
Other languages
English (en)
Inventor
Rolf Keltjens
Marinus Jacobus Maria Oosterbaan
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR039164A1 publication Critical patent/AR039164A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a un compuesto maleato de venlafaxina, a una composición farmacéutica que comprende un compuesto maleato de venlafaxina y un excipiente farmacéuticamente aceptable, a un método para tratar una enfermedad o condición tratable con venlafaxina, que comprende administrar a un paciente en necesidad de la misma una cantidad efectiva de un compuesto maleato de venlafaxina, a una sal de venlafaxina de baja solubilidad en agua distinta del besilato de venlafaxina, a una composición farmacéutica que comprende un compuesto sal de venlafaxina de baja solubilidad en agua, distinto del besilato de venlafaxina y un material de matriz hidrófila, y al uso del maleato de venlafaxina o sal de venlafaxina de baja solubilidad en agua distinta del besilato de venlafaxina como un medicamento.
ARP030101072A 2002-03-28 2003-03-27 Sales de venlafaxina de baja solubilidad en agua AR039164A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36770402P 2002-03-28 2002-03-28
US37244702P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
AR039164A1 true AR039164A1 (es) 2005-02-09

Family

ID=28678193

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101072A AR039164A1 (es) 2002-03-28 2003-03-27 Sales de venlafaxina de baja solubilidad en agua

Country Status (4)

Country Link
US (1) US6696496B2 (es)
AR (1) AR039164A1 (es)
AU (1) AU2003226751A1 (es)
WO (1) WO2003082805A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
EP1502587B1 (en) * 2003-07-30 2006-08-23 Pharmathen S.A. Sustained release formulation for Venlafaxine hydrochloride
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
CZ295243B6 (cs) * 2003-12-03 2005-06-15 Zentiva, A.S. Potahovaná tableta s obsahem venlafaxinu nebo jeho solí s řízeným uvolňováním
WO2005074895A1 (en) * 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
US7947739B2 (en) * 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
US20050215551A1 (en) * 2004-03-25 2005-09-29 Solvay Pharmaceuticals B.V. 1-[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of movement disorders
AR049478A1 (es) * 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
WO2006136927A1 (en) * 2005-06-22 2006-12-28 Glenmark Pharmaceuticals Limited Extended release formulations comprising venlafaxine
CA2625832A1 (en) * 2005-10-19 2007-04-26 Vinod Kumar Kansal Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
WO2007102169A1 (en) * 2006-03-08 2007-09-13 Jubilant Organosys Limited Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
EP2074993A1 (en) 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxine-containing film-coated modified-release tablets
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011057133A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Fragmented hydrogels
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
KR102146233B1 (ko) 2010-07-23 2020-08-21 그뤼넨탈 게엠베하 ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8902209D0 (en) 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
PT1153603E (pt) 1993-06-28 2007-01-31 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
AU9062998A (en) * 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
UA77145C2 (en) 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
CN1225356A (zh) 1998-12-15 1999-08-11 华东理工大学 1－[2－氨基－1－(对甲氧苯基)乙基]环己醇的合成方法
DK1466889T3 (da) * 1999-04-06 2008-09-08 Sepracor Inc O-Desmethylvenlafaxin-succinat
WO2000076955A1 (en) 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
CN1240206A (zh) 1999-06-17 2000-01-05 华东理工大学 1－[2－(二甲氨基)－1－(4－甲氧基苯基)乙基]环已醇盐酸盐的制备方法
ES2152902B1 (es) 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
EP1334082A4 (en) 2000-10-19 2006-02-01 Teva Pharma CRYSTALLINE BASIS OF VENLAFAXINE AND NEW POLYMORPHS OF VENLAFAXINE HYDROCHLORIDE AND PREPARATION THEREOF

Also Published As

Publication number Publication date
US6696496B2 (en) 2004-02-24
WO2003082805A1 (en) 2003-10-09
AU2003226751A1 (en) 2003-10-13
US20030190353A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR032912A1 (es) Formulacion farmaceutica
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR033688A1 (es) Composicion parenteral reconstituible
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
GT200600263A (es) Regimen de dosificacion para prasugrel
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR036312A1 (es) Composicion farmaceutica
ECSP077843A (es) Tratamiento o prevención del prurito
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
AR040515A1 (es) Formula farmaceutica topica estabilizada con contenido de ketoprofeno
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal